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Abstract 
Gene expression within a cell population can be directly altered through gene delivery 
approaches. Traditionally for nonviral delivery, plasmids or siRNA molecules, encoding or 
targeting the gene of interest, are packaged within nanoparticles. These nanoparticles are 
then delivered to the media surrounding cells seeded onto tissue culture plastic; this tech-
nique is termed bolus delivery. Although bolus delivery is widely utilized to screen for ef-
ficient delivery vehicles and to study gene function in vitro, this delivery strategy may not 
result in efficient gene transfer for all cell types or may not identify those delivery vehi-
cles that will be efficient in vivo. Furthermore, bolus delivery cannot be used in applica-
tions where patterning of gene expression is needed. In this chapter, we describe methods 
that incorporate material surfaces (i.e., surface-mediated delivery) or hydrogel scaffolds 
(i.e., hydrogel-mediated delivery) to efficiently deliver genes. This chapter includes pro-
tocols for surface-mediated DNA delivery focusing on the simplest and most effective 
methods, which include nonspecific immobilization of DNA complexes (both polymer and 
lipid vectors) onto serum-coated cell culture polystyrene and self-assembled monolayers 
of alkanethiols on gold. Also, protocols for the encapsulation of DNA/cationic polymer 
nanoparticles into hydrogel scaffolds are described, including methods for the encapsu-
lation of low amounts of DNA (<0.2 μg/μL) and high amounts of DNA (>0.2 μg/μL) since 
incorporation of high amounts of DNA poses significant challenges due to aggregation. 
Keywords: Gene delivery, Hydrogel, Surface-mediated, Transfection, Nonviral  
1. Introduction 
Gene expression within a cell population can be directly altered through gene 
delivery approaches, which have tremendous potential for therapeutic applica-
tions, such as gene therapy to correct genetic deficiencies or tissue engineer-
ing scaffolds, where gene delivery can present chemical factors to guide tissue 
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formation in regeneration matrices for treatment of organ loss and failure. Fur-
thermore, gene delivery is often critical to research applications, such as func-
tional genomics, cell culture studies, and biotechnological assays. Gene deliv-
ery can be performed with both viral and nonviral vectors, the latter of which 
are the focus of the techniques described in this chapter. Traditionally for non-
viral delivery, plasmids or siRNA molecules, encoding or targeting the gene of 
interest, are packaged within nanoparticles. These nanoparticles are then deliv-
ered to the media surrounding cells seeded onto tissue culture plastic; this tech-
nique is termed bolus delivery (Figure 1). Although bolus delivery is widely uti-
lized to screen for efficient delivery vehicles and to study gene function in vitro, 
this delivery strategy may not result in efficient gene transfer for all cell types 
or may not identify those delivery vehicles that will be efficient in vivo. Further-
more, bolus delivery cannot be used in applications where patterning of gene 
expression is needed. In this chapter, we describe methods that incorporate ma-
terial surfaces (i.e., surface-mediated delivery) or hydrogel scaffolds (i.e., hydro-
gel-mediated delivery) to efficiently deliver genes (Figure 1). 
Surface-mediated delivery, also termed solid-phase delivery or reverse trans-
fection, refers to the delivery of nucleic acid nanoparticles from a surface or bio-
material that supports cell adhesion. DNA nanoparticles are immobilized to the 
surface or biomaterial and cells are plated directly on top of the immobilized 
nanoparticles (Figure 1), which enhances the extent of transgene expression, 
along with increasing cell viability (1). This method of delivery was first described 
in 2002 using a specific avidin–biotin bond to tether nanoparticles to surfaces (2, 
3) and was later extended to nonspecific absorption of the nanoparticles to a va-
riety of biomaterial surfaces (1, 4–10). Nonspecific adsorption of nanoparticles is 
accomplished through noncovalent mechanisms (1, 4–14), including hydrophobic, 
Figure 1. Bolus, surface- and hydrogel-mediated gene delivery.  
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electrostatic, and van der Waals interactions. Nonspecific binding depends upon 
the molecular composition of the vector (e.g., lipid versus polymer) and the rela-
tive quantity of each (e.g., nitrogen-to-phosphate ratio or N/P), as well as prop-
erties of the surface (e.g., hydrophilicity, charge, presence of serum proteins). 
In surface-mediated delivery, DNA is concentrated at the delivery site and 
targeted to cells adhered to the substrate (1–3, 15). The major advantages of 
surface-mediated DNA delivery are the following: (1) decreased nucleic acid 
nanoparticle aggregation and degradation, since nanoparticles can be produced 
in the most favorable buffer for their formation and then immobilized to the sur-
face, which preserves the size observed in solution and avoids exposure of the 
particles in solution to the cell culture media, which often induces aggregation 
and decomplexation; (2) cells cultured on the substrate are exposed to elevated 
DNA concentrations within the local microenvironment (but typically overall con-
centration of DNA is minimized when compared to bolus techniques), which en-
hances transfection and minimizes cytotoxicity (1–10, 16) ; (3) elimination of mass 
transport limitations for the nanoparticles to reach the cell; and (4) immobiliza-
tion of DNA complexes to substrates allows for the ability to pattern transfection 
(9, 17), allowing for spatial control of gene delivery, which is critical for biotech-
nological and tissue engineering applications. Below, the reader will find proto-
cols for surface-mediated DNA delivery focusing on the simplest and most ef-
fective methods, which include nonspecific immobilization of DNA complexes 
(both polymer and lipid vectors) onto serum-coated cell culture polystyrene and 
self-assembled monolayers (SAMs) of alkanethiols on gold. 
Hydrogel-mediated delivery has been studied for over a decade primar-
ily through the encapsulation of naked DNA during hydrogel formation. Na-
ked DNA has been successfully incorporated inside hydrogels composed of 
collagen (18), pluronic-hyaluronic acid (19), dimethacrylated poly(lactic acid)-b-
poly(ethylene glycol)-b-poly(lactic acid) triblock copolymers (20), alginate (21), 
oligo(polyethylene glycol) fumarate (22), and engineered silk elastin (23). Al-
though naked DNA has shown gene expression and ability to guide regeneration 
in vivo (18, 24), limitations with low gene transfer efficiency and rapid diffusion 
of the DNA from the hydrogel scaffold motivated the use of DNA nanoparticles 
instead of naked DNA. DNA condensed either with cationic peptides, lipids, or 
polymers has been introduced into fibrin hydrogels (25–29), enzymatically de-
gradable PEG hydrogels (30), and PEG-hyaluronic acid hydrogels (26). The de-
livery of genes from hydrogel scaffolds is becoming an attractive route to in-
troduce foreign genes to cells for several reasons. First, in the biotechnology 
area, where new delivery agents are being investigated for in vivo gene trans-
fer, the delivery of genes inside a matrix may be a better model for in vivo gene 
transfer. For example, hydrogels can be used to recreate disease models in vi-
tro, including multiple cell types and complex extracellular matrices (e.g., cancer 
and organoid models). Second, in tissue engineering and regenerative medicine 
applications, it is often desired to transfect cells either infiltrating the scaffold 
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(endogenous) or that are transplanted. In the case of endogenous cell transfec-
tion, the hydrogel scaffold serves as a depot that contains genes or siRNA that 
can transfect cells as the cells infiltrate the scaffold or the matrix is degraded 
and the genes or siRNA are released. In the case of transplanted cell transfec-
tion, the matrix and cells are encapsulated together. The goal here is to transfect 
the transplanted cells at a later time to induce their differentiation or the differ-
entiation of nearby cells. Below, the reader will find protocols for the encapsula-
tion of DNA/cationic polymer nanoparticles into hydrogel scaffolds. We divide 
the encapsulation into low amounts of DNA (<0.2 μg/μL) and high amounts of 
DNA (>0.2 μg/μL) since incorporation of high amounts of DNA poses significant 
challenges due to aggregation.  
2. Materials 
For surface-mediated delivery, the following reagents are necessary. 
2.1. Dulbecco’s Phosphate-Buffered Saline (PBS): 1× Solution containing 2.67 mM 
KCl, 1.47 mM KH2PO4, 137.93 mM NaCl, and 8.1 mM Na2HPO4 with no cal-
cium or magnesium, prepared in MilliQ water, pH 7.4. Stored at room tem-
perature. Sterile filtered. 
2.2. 10% Fetal Bovine Serum (FBS): 10% FBS prepared in 1× PBS (prepared as 
described above). Prepare sterilely and aliquots may be stored at 4°C for a 
short term (<2 weeks) or −20°C for longer time periods. 
2.3. TBS Buffer: 100 mM tris(hydroxymethyl)aminomethane–HCl, pH 7.4, 150 mM 
NaCl. 
2.4. Opti-MEM® I Reduced Serum Media (1×) (Invitrogen™ by Life Technologies) 
(see Note 1). 
2.5. Tissue Culture Polystyrene (TCPS): Delivery can be performed on any TCPS 
substrate (microscope slides, 6-, 12-, 24-, 48-, or 96-well plates or dishes, 
see Note 2), with the requirement that it is “tissue culture” polystyrene (in-
dicating that it has been surface modified, typically through corona dis-
charge or gas-plasma, to promote protein and cell adhesion (31, 32)). These 
reagents are needed for the preparation of SAMs: 
2.6. Ethanol: 200 Proof, filtered through a 0.22 μm filter, degassed with N2 gas 
for at least 15 min. 
2.7. Argon Gas: It is recommended to store the alkanethiol solutions and gold 
substrates under argon gas. Do not store SAMs  under argon as it can cause 
toxicity issues. 
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2.8. 11-Mercaptoundecanoic Acid (MUA): 2 mM solution in ethanol, described 
above. 
2.9. Gold Substrates: Gold-coated glass slides, composed of a titanium adhesion 
layer and 100–500 Å of gold, can be purchased commercially or prepared 
using e-beam evaporation. Gold-coated slides should be cut into smaller 
pieces with a diamond-tipped glass cutter so that pieces fit into standard 
48-well tissue culture plates (for this protocol, may be adjusted based on 
experimental setup). 
The following reagents are used for DNA nanoparticle preparation: 
2.10. Reporter Plasmid DNA: Transfection is typically assessed by either fluores-
cent reporter genes (e.g., GFP or DS-red) or luminescent reporter genes 
(e.g., Firefly or Renilla Luciferase), or both. Plasmids are available commer-
cially with these reporter genes, typically driven by CMV promoters. These 
plasmids can be expanded using commercially available prep kits such as 
the endotoxin free Giga Prep kit from Qiagen (see Note 3) and their ex-
pression assayed using fluorescent microscopy or commercially available 
kits. DNA is typically stored in TE buffer (10 mM Tris–Cl, pH 7.4–8.0, 1 mM 
EDTA, pH 8.0) at −20°C. Prepare stock solution in TE of 1 μg/ μL for com-
plexation protocol below. 
2.11. Branched Poly(Ethylene Imine) (PEI) Stocks: 
1. Prepare 10 mg/mL solution of PEI (Sigma, branched, 25 kDa) in 0.1 M 
NaHCO3 (sodium bicarbonate) (pH 8.2). Branched PEI is a liquid. 
2. Using 6,000–8,000 MWCO tubing, dialyze the PEI against MilliQ water for 
24 h, changing water at least three times over the course of dialysis. 
3. After dialysis, lyophilize the PEI solution. 
4. When lyophilization is complete, weigh the lyophilized PEI and resuspend 
in TBS buffer at 1 mg/mL. Store stocks at −20°C. 
2.12. Linear PEI Stocks: Linear PEI (Polysciences, 25 kDa) comes as a very basic 
polymer with Cl– as a counterion. To remove excess Cl– ions, which would 
be present at neutral pH, the PEI is precipitated and dialyzed. 
1. Dissolve 100 mg of PEI in 10 mL of DI water at room temperature. While 
stirring the solution bring the pH down to 7.4 using 1 N HCl to help 
dissolve it. 
2. Precipitate the PEI by raising the pH to 12 with 1 N NaOH. Keep stirring 
the solution. The solution will turn white and blurry, but still stay in 
suspension. The PEI will be neutral since it will be deprotonated and 
it will become hydrophobic and insoluble in water. 
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3. Using 6,000–8,000 MWCO tubing, dialyze the precipitated PEI against DI 
water, pH 12 for 1 day to remove the chlorine ion (change water 2× 
every 2–3 h using 3–4 L DI water, pH 12 each time) and for 2–3 days 
against DI water (pH 7) to re-protonate. 
4. The PEI will become partially soluble in water again. After dialysis lyoph-
ilize the PEI solution. 
5. Redissolve the entire 100 mg in 10 mL water or, alternatively, weigh out 
the desired amount of powder and dissolve it in water for a 10 mg/mL 
solution. About 10 μL of HCl per 3 mg of PEI will be required to help 
it dissolve. After the PEI is dissolved adjust the pH to 7.4. 
6. Aliquot 1 mg/tube and lyophilize the PEI solution a second time. Store 
the lyophilized stocks at −20°C and resuspend in water or the desired 
buffer/saline solution. A typical final concentration is 1 μg/μL. Adjust 
final pH to 7.4. 
2.13. Lipofectamine™ 2000 (Invitrogen™ by Life Technologies) is used (see Note 
4). 
Materials for hydrogel-mediated delivery are the following: 
2.14. Triethanol amine (TEOA) Buffer: 0.3 M TEOA (stored under argon). Pi-
pette 19.2 mL of ultrapure water into a beaker, add 0.8 mL of TEOA, and 
mix. Set pH to 8.6–8.7 with 37% HCl (the initial pH is 9–10 and requires 
20–40 droplets). Sterile filter the final buffer. Use immediately or alterna-
tively the buffer can be placed into aliquots and stored at −20°C under 
argon until use. 
2.15. PEG-VS: 
1. Dissolve four-arm PEG-OH in tetrahydrofuran (THF) under inert atmo-
sphere and heat to reflux in a Soxhlet apparatus filled with molecu-
lar sieves for 3–4 h. 
2. Allow the solution to cool to the touch and add sodium hydride (NaH; 
please note that NaH is a highly flammable material when in con-
tact with water), at fivefold molar excess over OH groups, followed 
by the addition of divinyl sulfone, at 50-fold molar excess over OH 
groups. 
3. Allow the reaction to continue at room temperature (RT) under argon at-
mosphere with constant stirring for 3 days. 
4. Neutralize the reaction solution with acetic acid, filter it, concentrate by 
roto-evaporation, and precipitate it in ice-cold diethyl ether. 
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5. Precipitation should be repeated three times to remove unreacted divi-
nyl sulfone. 
6. Dry the final product under vacuum and store under argon at −20°C. 
7. The degree of functionalization is confirmed with 1H NMR (in CDCl3): 3.6 
ppm (PEG backbone), 6.1 ppm (d, 1H, CH2), 6.4 ppm (d, 1H, CH2), and 
6.8 ppm (dd, 1H, –SO2CH). 
2.16. HA-AC: 
1. Dissolve 2 g hyaluronic acid (HA) (60 kDa) in 400 mL DI water. 
2. Add 36.3 g adipic acid dihydrazide (ADH, 21.8 molar excess over car-
boxylic acid groups), dissolve completely, and adjust the pH to 4.75 
with 1 N HCl. 
3. Add 4 g 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydro-
chloride (EDC, 3.95 molar excess over carboxylic acid groups) as 
a catalyst. 
4. Maintain the pH at 4.75 until it becomes stable (~2 h) and let it react 
overnight. 
5. Purify HA–ADH through dialysis (6,000–8,000 MWCO) against DI water 
for 3 days, changing the water at least 2× per day. 
6. Collect the purified HA–ADH and lyophilize it until completely dry (~2 
days). Dry HA–ADH can be stored at −20°C until the next step. 
Using these reaction conditions, ~40% of the carboxyl groups are modified with ADH based 
on the trinitrobenzene sulfonic acid (TNBSA, Pierce) assay. 
7. Make reaction buffer: 10 mM HEPES with 150 mM NaCl and 10 mM EDTA 
at pH 7.2. 
8. Dissolve HA–ADH in reaction buffer for a final concentration of ~5.5 
mg/mL. Mix using a stir bar and plate for about 2 h to completely 
dissolve. 
9. Weigh out 1 g N-acryloxysuccinimide (NHS-Ac, ~3–4 molar excess over 
amine groups) and dissolve in 10 mL DMSO. Keep on ice. 
10. React HA–ADH with NHS-Ac by adding 1 mL NHS-Ac in DMSO every 
15–20 min and let it react overnight. 
11. Purify HA-AC through dialysis (6,000–8,000 MWCO) against DI water 
for 3 days, changing the water at least 2× per day. 
12. Collect the purified HA-Ac and lyophilize it until completely dry (~2 
days). Dry HA-Ac can be stored at −20°C until used. 
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The degree of functionalization should be confirmed with 1H NMR (in D2O). 
2.17. Peptide Crosslinker Aliquots: Michael addition chemistry can be used to 
cross-link PEG-VS or HA-AC into a hydrogel. Any di-thiol-containing mol-
ecule would work; however, to make the hydrogel degradable by cells pro-
tease degradable peptides are generally used. The peptide Ac-GCRDG-
PQGIWGQDRCG-NH2 (synthesized through solid-phase peptide synthesis 
or commercially purchased) has been used by several groups (for reviews 
see Refs. 33, 34). Aliquots of the peptide are made to prevent its exposure 
to oxygen and disulfide bond formation. The peptide crosslinker powder 
is dissolved in 0.1% TFA, aliquoted into microcentrifuge tubes, and ly-
ophilized. Because TFA is a volatile salt the resulting lyophilized powder 
contains only the peptide. The amount to be aliquoted depends on the 
number of cross-links desired or r ratio, which is the molar ratio of –SH 
groups to –VS or –AC groups. For example, for 100% modified PEG-VS 
hydrogels with 6% PEG an r ratio close to 1 is used, while for a 40% mod-
ified HA-AC with 3% gel an r ratio close to 0.3 is used. Typically enough 
material is aliquoted to be used in a single use. No freeze–thaw cycles 
are recommended. 
2.18. RGD Peptide Aliquots: Michael addition is used to modify PEG-VS or 
HA-AC with cell adhesion peptides such as RGD. Similar to the peptide 
crosslinker aliquots, RGD peptide aliquots are made to prevent disulfide 
bond formation. RGD peptide powder (Ac-GCGYGRGDSPG-NH2, synthe-
sized through solid-phase peptide synthesis or commercially purchased) 
is dissolved in 0.1% TFA, aliquoted into microcentrifuge tubes, and lyoph-
ilized. The amount to be aliquoted depends on the amount of RGD de-
sired inside the hydrogel material (typically 30–500 μM final concentra-
tion for HA hydrogels and 30–200 μM for PEG-VS gels). Typically enough 
material is aliquoted to be used in a single use. No freeze–thaw cycles 
are recommended. 
2.19. Reporter Plasmid DNA: To assess transfection from cells seeded inside 
hydrogel scaffolds, secreted proteins are recommended. The two most 
commonly used are secreted alkaline phosphatase mammalian expres-
sion vector (pSEAP, Genlantis, San Diego, CA) and Gaussia luciferase 
(pGLUC, New England Biolabs, Ipswich, MA). Both plasmids can be ex-
panded using commercially available prep kits such as the endotoxin 
free Giga Prep kit from Qiagen and their expression assayed using com-
mercially available kits.  
2.20. Sigmacote-Coated Slides: 
1. Prepare Sigmacote® -coated glass slides by immersion of slides in Sig-
macote® solution using a 50 mL conical tube for 1 min and air drying 
for 3 min. Repeat this 3× for each slide (see Note 5). 
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2. After the third coating, place slides into oven above 100°C for 2 h to over-
night to allow for complete drying. 
3. Wash the slides with ethanol to sterilize before use. You should notice 
that the water slides off the slide easily. 
2.21. Agarose: Dissolve 670 mg low-melting-point agarose in 1 L MQ H2O, allow 
1–2 h to mix using a stir bar and stir plate, and filter solution using a 0.22 
μm filter. Store stock solution at RT. 
2.22. Sucrose: Dissolve 3.5 g sucrose in 10 mL Millipore water and filter solution 
using a 0.22 μm filter. Store stock solution at 4°C.  
3. Methods 
3.1. Surface-Mediated DNA Delivery 
For substrate-mediated gene delivery, the properties of the surface are critical to both im-
mobilization strategies and transfection efficiencies, as are the properties of the DNA com-
plexes. Surface-mediated delivery has been reported on a variety of surfaces, including SAMs 
(9, 10), and standard tissue culture polystyrene (PS) plastic (1, 4–6, 35). As the highest trans-
fection levels were reported on carboxylic acid-terminated SAMs (9) and serum-coated PS 
(1), methods for these two surfaces are reported in this chapter. Methods are included for 
both polymer- and lipid–DNA complexes (Figure 2).  
3.1.1. For Surface Preparation of Serum-Coated Polystyrene Proceed as Follows (See Also 
Notes 6–8) 
1. Add 100 μL of 10% FBS per cm2 (e.g., add 100 μL per well of a 48-well plate). 
2. Let plate incubate at room temperature for 2 h (see Note 9). 
3. After incubation, remove 10% FBS solution from wells and wash with 1× PBS (see 
Note 10).  
3.1.2. For Surface Preparation of COO–-Terminated SAMs Proceed as Follows (See Note 11) 
1. Prepare 2 mM solution of MUA in filtered, degassed ethanol (see Note 12). 
2. Wash gold substrates with copious amounts of acetone followed by ethanol. Dry 
gold substrates under a stream of N2 gas. 
3. Place gold surfaces into 2 mM MUA solution and allow monolayer formation to pro-
ceed for 45 min (see Note 13). 
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4. After monolayer formation, rinse SAMs with ethanol and dry surfaces under stream 
of N2 gas. 
5. Allow surfaces to equilibrate in PBS for 15 min to ensure deprotonation of terminal 
functional groups at physiological pH. 
Figure 2. Visual protocol for surface-mediated gene transfer.  
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3.1.3. PEI–DNA Complexes Are Prepared with Branched PEI, 25 kDA with 3 m g of DNA in 300 
m L Per Well at an N/P of 20 (See Notes 14 and 15) 
1. Add 177 μL of TBS (see Note 16) to a microfuge tube labeled “DNA.” Add 3 μL of plas-
mid DNA stock solution (1 μg/μL) and mix by pipetting up and down (see Note 17). 
2. Add 111.8 μL of TBS to a microfuge tube labeled “PEI.” Add 8.2 μL of PEI stock solu-
tion (1 mg/mL) and mix by pipetting up and down (see Note 18). 
3. Add the contents of the PEI tube to the DNA solution (DNA tube) (see Note 19), 
vortex gently for 10 s, and let complexes form for 15 min at room temperature 
(see Note 20).  
3.1.4. Lipofectamine 2000–DNA Complexes Are Generated with 1 m g of DNA in 300 m L Per 
Well, and a DNA:Lipofectamine 2000 Ratio of 1:2 (See Notes 14 and 15) 
1. Add 147 μL of Opti-MEM media to a microfuge tube labeled “DNA.” Add 3 μL of 
plasmid DNA stock solution (1 μg/μL) and mix by pipetting up and down. 
2. Add 144 μL of Opti-MEM media to a microfuge tube labeled “LF2000.” Add 6 μL of 
Lipofectamine 2000 stock solution and mix by pipetting up and down. 
3. Add the contents of the LF2000 tube to the DNA solution (DNA tube) (see Note 
21), pipette up and down, and let complexes form for 20 min at room temper-
ature (see Note 20).  
3.1.5. After Formation, Complexes are Immobilized 
1. Once complex formation is complete (for either PEI–DNA complexes OR Lipo-
fectamine 2000–DNA Complexes), add 300 μL of complexes to surfaces (for ei-
ther FBS-coated PS or COO–-terminated SAMs) and let deposit for 2 h at room 
temperature. 
2. After 2 h of complex deposition, remove unbound complexes by washing surfaces 
twice with TBS (for PEI–DNA complexes) or Opti-MEM (for Lipofectamine 2000–
DNA complexes) (see Notes 22 and 23).  
3.1.6. After Complex Immobilization to Surfaces, Cells Are Seeded onto the Complexes and 
the Transfection Efficiency Analyzed 
1. Seed 300 μL of cells in each well (15,000 cells/well) (see Note 24). 
2. Incubate cells at 37°C and 5% CO2 for 24–48 h. 
3. Assay for transfection using fluorescence microscopy or luminescence assay (depend-
ing on the reporter gene present on plasmid) after 24–48 h (see Notes 25–27).   
3.2. Hydrogel-Mediated Gene Delivery: Direct Encapsulation (<0.2 m g DNA/ m L 
Hydrogel) 
The encapsulation of DNA into hydrogel scaffolds will require different protocols depending 
on the quantity of DNA loaded. Low amounts of DNA, <0.2 μg/μL, may be loaded into hy-
drogel scaffolds without significant aggregation. The following protocol is for the synthesis 
of a 100 μL 3% HA or 100 μL 6% PEG hydrogel scaffold with 0.05 μg DNA/ μL of hydrogel. 
We will be incorporating DNA complexed with linear PEI at an N/P ratio of 7 (see Note 28). 
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3.2.1. HA-RGD/PEG-RGD Is Synthesized as Follows 
1. Weight out and dissolve HA-AC (3 mg) or PEG-VS (6 mg) into 38 μL or 27 μL TEOA 
buffer. For the HA polymer, incubate for 20 min at 37°C to speed up the dissolu-
tion process. Ensure that polymer solution pH is 8.2–8.3 at this point. 
2. Take an RGD peptide aliquot out from the −30°C freezer and place it on ice. 
3. Use the dissolved HA-AC or PEG-VS to dissolve the RGD aliquot. Vortex thoroughly 
and allow to incubate for 30 min at 37°C. 
4. Add 5 μL of 0.3 M TEOA to HA-RGD (see Note 29). 
5. Keep the newly reacted HA-RGD or PEG-RGD on ice.   
3.2.2. Thereafter, DNA Nanoparticles (Polyplexes) Are Formed at an N/P Ratio of 7 
1. Place 5 μg of DNA into a sterile microcentrifuge tube and dilute to 10 μL in Milli-
pore water. 
2. Place 4.57 μg of PEI into a sterile microcentrifuge tube and dilute to 8 μL in Milli-
pore water. 
3. Add the PEI solution to the DNA solution, vortex gently for 15 s, and incubate for 10 
min at room temperature. After the 10-min incubation place the DNA nanopar-
ticles (polyplexes) on ice for at least 5 min.  
3.2.3. The Hydrogel Is Synthesized as Follows 
1. Take a crosslinker aliquot out of the freezer and place in −20°C cooler. 
2. Subculture cells and dilute to 25,000 cells/ μL or 20,000 cells/ μL. The final desired 
cell concentration in hydrogel is 1,000–5,000 cells/ μL of gel. Place cells on ice. 
The next steps must be done quickly to avoid premature gelation in the tube! 
3. Bring the polyplex solution to 0.3 M TEOA by adding 2 μL of 3 M TEOA and imme-
diately add the entire 20 μL polyplex solution to the HA-RGD or the PEG-RGD. 
Place on ice. 
4. Add 20 μL or 31 μL of the 25,000 cells/μL or 20,000 cells/μL cell stock to the HA-
RGD/DNA nanoparticle or PEG-RGD/DNA nanoparticle solution and mix thor-
oughly but gently. Place on ice (see Note 30). 
5. Dissolve the crosslinker in 17 μL or 22 μL of ice-cold TEOA buffer and quickly add 
to the HA-RGD/Cell/polyplex suspension or the PEG-RGD/Cell/polyplex suspen-
sion. Mix thoroughly using a positive displacement pipette or a wide orifice tip 
(see Note 31). The final gel solution should have a pH of 8.0–8.1. 
6. Quickly cast the desired gels either as one large 100 μL gel or several small gels into 
the gel caster (Figure 3). Place gel caster at 37°C for 30 min.  
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7. Place the gel(s) into the desired tissue culture plate size. The large gel can be cut 
with a biopsy punch to result in several small gels. 96- or 48-well plates are rec-
ommended for culturing to avoid diluting out the reporter protein. 
8. By collecting the media of the cells and performing the appropriate assay, Phos-
pha-light SEAP reporter gene assay system or Biolux gaussia luciferase assay kit, 
transfection can be monitored. Gene transfer has been observed as early as 2 
days and as late as 7 days depending on the cell type and how well the cells mi-
grate through the material. 
Figure 3. Visual protocol for hydrogel-mediated gene transfer for low concentrations of DNA.  
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3.3. Hydrogel-Mediated Gene Delivery: Caged Nanoparticle Encapsulation 
For high concentrations of DNA polyplexes direct encapsulation results in severe aggrega-
tion. The Segura laboratory has developed a process that can be used to encapsulate high 
concentrations, up to 5 μg/ μL, into hydrogel scaffolds (36). As an example, the following 
protocol is for the synthesis of 100 μL HA-AC/MMP hydrogels with 100 μg of DNA or 100 
μL PEG-VS/MMP hydrogels with 100 μg of DNA. First, polyplex powder is prepared: 
1. Dilute pDNA (100 μg) with 1,000 μL MilliPore water H2O in a 15 mL conical tube. 
2. In a separate 15 mL tube, add 100 μL (350 mg/mL) sucrose and 2,200 μL MilliPore 
water. 
3. Add 91.3 μL of L-PEI to the diluted sucrose solution. 
4. Add the dilute PEI/sucrose solution to the pDNA solution, vortex for 15 s, and in-
cubate at room temperature for 15 min. 
5. Add 1.5 mL of (.67 mg/mL) agarose to DNA/PEI solution, vortex for 10 s, and im-
mediately dip into liquid nitrogen. 
6. Allow 5 min to freeze completely and lyophilize. 
7. Remove tubes from lyophilizer and place tubes at −20°C until ready for use.   
3.3.1. HA-RGD/PEG-RGD Synthesis Is Carried Out Slightly Different as Described in Sub-
heading 3.2 
1. Weight out and dissolve HA-AC (3 mg) or PEG-VS (6 mg) into 38 μL or 27 μL 
TEOA buffer. For the HA polymer incubate for 20 min at 37°C to speed up the 
dissolution process. 
2. Take an RGD peptide aliquot out from the −20°C freezer and place it on ice. 
3. Use the dissolved HA-AC or PEG-VS to dissolve the RGD aliquot. Vortex thor-
oughly and allow to incubate for 30 min at 37°C. 
4. Add 25 μL of 0.3 M TEOA to HA-RGD (see Note 29). 
5. Keep the newly reacted HA-RGD or PEG-RGD on ice.   
3.3.2. Hydrogels Are Synthesized in the Following Way 
1. Take a crosslinker aliquot out of the freezer and place in −20°C cooler. 
2. Subculture cells and dilute to 25,000 cells/μL or 20,000 cells/μL. The final desired 
cell concentration in hydrogel is 1,000–5,000 cells/ μL of gel. Place cells on ice. 
The next steps must be done quickly to avoid premature gelation! 
3. Place polyplex powder in a 1.5 mL microcentrifuge tube and mix with HA-RGD/
cell or PEG-RGD/cell suspension. 
4. Add 20 μL or 31 μL of the 25,000 cells/μL or 20,000 cells/μL cell stock to the HA-
RGD/DNA nanoparticle or PEG-RGD/DNA nanoparticle solution and mix thor-
oughly but gently. Place on ice.  
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5. Dissolve the crosslinker in 17 μL or 22 μL of ice-cold TEOA buffer and quickly add 
to the HA-RGD/Cell/polyplex suspension or the PEG-RGD/Cell/polyplex sus-
pension. Mix thoroughly using a positive displacement pipette or a wide orifice 
tip (see Note 30). The final gel solution should have a pH of 8.0–8.1. 
6. Quickly cast the desired gels either as one large 100 μL gel or several small gels 
into the gel caster (Figure 4). Place gel caster at 37°C for 30 min.  
Figure 4. Visual protocol for hydrogel-mediated gene transfer for high concentrations of DNA.    
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7. Place the gel(s) into the desired tissue culture plate size. The large gel can be cut 
with a biopsy punch to result in several small gels. 96- or 48-well plates are 
recommended for culturing to avoid diluting out the reporter protein. 
8. By collecting the media of the cells and performing the appropriate assay, Phos-
pha-light SEAP reporter gene assay system or Biolux gaussia luciferase assay 
kit, transfection can be monitored. Gene transfer has been observed as early as 
2 days and as late as 7 days depending on the cell type and how well the cells 
migrate through the material.   
4. Notes 
1. Invitrogen recommends the use of Opti-MEM® I Reduced Serum Media for trans-
fection with Lipofectamine 2000 (37). We have found that its use does enhance 
transfection, but for many cell lines other serum-free media can be used for for-
mation of the lipoplexes. 
2. Most of our protocols have been optimized with and utilize 48-well plate format. 
The least effective well for surface-mediated delivery is the 96-well plate, as those 
wells are often not perfectly flat and thus complexes deposit irregularly. 
3. Any protocol for DNA preparation from bacterial cultures is sufficient, but “endo-
toxin-free” buffers are essential for transfection-grade DNA. 
4. This chapter includes protocols for one lipid-based transfection reagent (Lipo-
fectamine 2000) and one polymer-based transfection reagent (PEI). However, 
surface-mediated delivery has also been accomplished with jet-PEI (3, 16), Li-
pofectamine LTX (35), FugeneHD (Rocher) (unpublished results), and Effectene 
(Qiagen) (35), as well as viral vectors (15, 38–43). The encapsulation of lipoplexes 
and jetPEI/DNA polyplexes into hydrogel scaffolds has also been possible using 
a similar protocol (36). 
5. After use, pour the Sigmacote® back into a dark glass bottle (not back into the clean 
stock solution). This Sigmacote can be reused 3–4×. 
6. Methods are per cm2, and can be scaled accordingly for different surface areas. 
7. These methods can be modified to other surfaces including poly(lactide-co-gly-
colide) (PLGA) (7, 8, 11, 42) and collagen (11, 43). 
8. This protocol can also be modified to use purified extracellular matrix/serum pro-
teins, including fibronectin, collagen, and laminin (5, 7), with fibronectin typically 
resulting in the highest transfection levels. 
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9. Serum incubation can proceed for longer periods of time, even overnight at 4°C, 
without negatively affecting transfection levels. 
10. Perform this step right before adding complexes, as described under “Subhead-
ing 3.1.6.” 
11. Incorporation of poly(ethylene glycol) groups into carboxylic acid-terminated SAMs 
may increase transfection (10). In this case, prepare SAMs by immersing gold 
substrates into a mixed alkanethiol solution containing both MUA as well as 
HS(CH2)11(OCH2CH2)6 OH, in ratios identical to what is desired in the final SAM 
(typically 40% or less of the PEGylated thiol). 
12. Prepare alkanethiol solution fresh for each experiment and use amber bottles or 
those covered with aluminum as thiols are light sensitive. Cover with argon if not 
used immediately. 
13. Typically we use gold substrates of ~0.5 cm2 cut from a gold-coated microscope 
slide, as described above. These small pieces of gold are best handled with three-
prong forceps. We typically form SAMs in foil-lined glass scintillation vials that 
contain 7–8 mL of MUA solution. 
14. Both DNA amount and N/P ratio (or DNA:lipid ratio) need to be optimized for each 
cell type; the conditions used in this chapter represent good starting optimiza-
tion points for NIH/3T3s; also these amounts are for a single well, so scale ac-
cordingly for multiple wells. For Lipofectamine™ 2000, Invitrogen recommends a 
Lipofectamine™/DNA ratio (μL/μg) between 0.5 and 5 for optimum transfection 
(37). For branched PEI, N/Ps are recommended between 10 and 25. 
15. Adsorption is typically 10–20% of total DNA added to surfaces (1, 9) ; thus use 
approximately 5–10 times as much DNA as would typically be used in bolus 
conditions. 
16. Can also use 150 mM NaCl to form polyplexes. 
17. 60% of total complex volume should be with DNA. 
18. 40% of total complex volume should be with PEI. 
19. This order of addition is critical to transfection success. 
20. During this time prepare surfaces for complex immobilization; for FBS-coated PS, 
remove the FBS and rinse with PBS as described above or for SAMs, incubate 
with PBS to ensure deprotonation. 
21. We have found that even for lipids this order of addition is critical to transfection 
success. 
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22. Longer adsorption times result in larger mass of DNA complexes immobilized, but 
can also be associated with loss of activity; thus adsorption time is another vari-
able that can be manipulated. 
23. Be sure that cell suspension is prepared and cells are ready to seed immediately 
after this rinsing step. 
24. Cell density is for NIH/3T3s; this value will need to be optimized for each cell type. 
25. Time after delivery to assay transfection may also need to be optimized. 
26. For transfection studies on SAMs, move each SAM to a new well before proceed-
ing with luminescence or protein assay to ensure that transfection is only mea-
sured in cells adhered to SAM and not on surrounding PS. 
27. For transfection studies on SAMs, gold quenching of fluorescence may limit ob-
servation of transfection by fluorescent reporter genes. To reduce quenching, be 
sure to use upright microscope or fix cells and then place SAMs face down into 
well before imaging. 
28. Encapsulation of polyplexes into fibrin, collagen, and UV cross-linked hydrogel 
scaffolds is also possible using the same protocols (36). 
29. This 5 μL or 25 μL volume could be used to introduce other factors to the hydro-
gel such as growth factors. Further, this volume could be added to the cell vol-
ume to make the cell stock less concentrated. 
30. The cell concentration in the gel and the cell concentration used in the stock solu-
tion should be optimized per cell type. For example, we have found that for MSCs 
25,000 cells/μL is the highest concentration that can be used before severe cell 
death is observed post encapsulation. It is recommended to make different cell 
stock concentrations and make hydrogels without DNA/siRNA nanoparticles to 
determine the ideal cell concentration. 
31. The amount of crosslinker added should be ~0.3 moles of thiol/mole of acrylate 
for the HA-AC hydrogel and 0.9 thiol/mole of vinyl sulfone for the PEG hydrogel. 
This is assuming a 40% modified HA molecule and a 100% modified PEG-VS poly-
mer. This ratio can be varied to make hydrogels with different mechanical prop-
erties. It is recommended to use a spreadsheet program such as Microsoft Excel 
to calculate the ratio of thiols to acrylate or vinyl sulfone. Further the amount of 
crosslinker added will also be dependent on the activity of the crosslinker. Since 
the crosslinkers are bi-thiol molecules they are easily oxidized into disulfides. To 
determine the activity of the crosslinker, a thiol quantification assay such as the 
Ellman’s assay should be performed. The moles of the crosslinker used to achieve 
a desired thiol/acrylate or vinyl sulfone ratio should be adjusted accordingly.   
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